LeMaitre Vascular, Inc. (NASDAQ:LMAT) Plans Quarterly Dividend of $0.16

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Thursday, August 1st, Zacks reports. Shareholders of record on Thursday, August 15th will be given a dividend of 0.16 per share by the medical instruments supplier on Thursday, August 29th. This represents a $0.64 annualized dividend and a yield of 0.75%. The ex-dividend date is Thursday, August 15th.

LeMaitre Vascular has raised its dividend by an average of 13.8% annually over the last three years and has increased its dividend annually for the last 13 consecutive years. LeMaitre Vascular has a payout ratio of 32.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect LeMaitre Vascular to earn $1.97 per share next year, which means the company should continue to be able to cover its $0.64 annual dividend with an expected future payout ratio of 32.5%.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded down $1.24 on Friday, hitting $85.01. 348,354 shares of the stock were exchanged, compared to its average volume of 157,693. LeMaitre Vascular has a 52-week low of $44.27 and a 52-week high of $91.76. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 56.30, a P/E/G ratio of 2.63 and a beta of 0.89. The company’s 50-day moving average price is $82.69 and its two-hundred day moving average price is $71.68.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The business had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same period in the previous year, the company posted $0.37 EPS. LeMaitre Vascular’s revenue was up 11.4% on a year-over-year basis. Equities analysts predict that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on LMAT. Roth Mkm restated a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a research note on Friday. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday. Finally, JMP Securities lifted their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research note on Friday, May 3rd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $83.71.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now directly owns 2,133,428 shares of the company’s stock, valued at $161,500,499.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 8,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the transaction, the chief executive officer now owns 2,079,128 shares in the company, valued at approximately $156,558,338.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the transaction, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 127,437 shares of company stock valued at $10,076,242. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.